Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: Roles of P-glycoprotein and cytochrome P450 3A inhibition

European Journal of Pharmaceutical Sciences

Volumn 50, Issue 3-4, 2013, Pages 429-439

  Zhao, Gang ^a   Huang, Jiangeng ^a   Xue, Kewen ^a   Si, Luqin ^a   Li, Gao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Absorption; Cytochrome P450 3A; Etoposide; P glycoprotein; Self microemulsifying drug delivery system

Indexed keywords

CREMOPHOR; CYTOCHROME P450 3A; ETOPOSIDE; MACROGOL 400; MULTIDRUG RESISTANCE PROTEIN; POLYSORBATE 80; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; CELL MEMBRANE FLUIDITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; INTESTINE ABSORPTION; INTESTINE PERFUSION; MALE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; CYTOCHROME P450 3A; ETOPOSIDE; P-GLYCOPROTEIN; SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL SURVIVAL; CYTOCHROME P-450 CYP3A; DRUG DELIVERY SYSTEMS; ETOPOSIDE; HUMANS; INTESTINAL ABSORPTION; KETOCONAZOLE; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; VERAPAMIL;

EID: 84883635817     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.08.016     Document Type: Article

References (42)

1. R.C. Bravo González, J. Huwyler, F. Boess, I. Walter, and B. Bittner In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam Biopharm. Drug Dispos. 25 2004 37 49 (Pubitemid 38159262)
2. W.N. Charman, and V.J. Stella Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules Int. J. Pharm. 34 1986 175 178
3. C.L. Cummins, L. Salphati, M.J. Reid, and L.Z. Benet In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model J. Pharmacol. Exp. Ther. 305 2003 306 314 (Pubitemid 36373865)
4. A. Dahan, and G.L. Amidon Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs Mol. Pharm. 6 2009 19 28
5. P.K. Dudeja, K.M. Anderson, J.S. Harris, L. Buckingham, and J.S. Coon Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity Arch. Biochem. Biophys. 319 1995 309 315
6. J. Fan, S. Liu, Y. Du, J. Morrison, R. Shipman, and K.S. Pang Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha,25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer J. Pharmacol. Exp. Ther. 330 2009 389 402
7. N. Gursoy, J.S. Garrigue, A. Razafindratsita, G. Lambert, and S. Benita Excipient effects on in vitro cytotoxicity of a novel paclitaxel self-emulsifying drug delivery system J. Pharm. Sci. 92 2003 2411 2418 (Pubitemid 37484767)
8. C. Hansch, A. Leo, and D. Hoekman Exploring QSAR-Hydrophobic, Electronic, and Steric Constants 1995 Amer. Chem. Soc Washington, DC
9. J.M. Henwood, and R.N. Brogden Etoposide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer Drugs 39 1990 438 490
10. E.D. Hugger, B.L. Novak, P.S. Burton, K.L. Audus, and R.T. Borchardt A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro J. Pharm. Sci. 91 2002 1991 2002 (Pubitemid 36254935)
11. S. Kishi, W. Yang, B. Boureau, S. Morand, S. Das, P. Chen, E.H. Cook, G.L. Rosner, E. Schuetz, C.H. Pui, and M.V. Relling Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia Blood 103 2004 67 72 (Pubitemid 38029919)
12. J. Kunta, J. Yan, V.D. Makhey, and P.J. Sinko Active efflux kinetics of etoposide from rabbit small intestine and colon Biopharm. Drug Dispos. 21 2000 83 93
13. C.K. Lee, S.H. Ki, and J.S. Choi Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin Biopharm. Drug Dispos. 32 2011 245 251
14. L.Y. Li, G.L. Amidon, J.S. Kim, T. Heimbach, F. Kesisoglou, J.T. Topliss, and D. Fleisher Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat J. Pharmacol. Exp. Ther. 301 2002 586 593 (Pubitemid 34429971)
15. M. Li, L. Si, H. Pan, A.K. Rabba, F. Yan, J. Qiu, and G. Li Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: assessed in vitro by everted gut sac and in situ by improved intestinal perfusion Int. J. Pharm. 403 2011 37 45
16. J.H. Lin, M. Chiba, and T.A. Baillie Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol. Rev. 51 1999 135 158
17. Y. Lu, J. Qi, and W. Wu Absorption, disposition and pharmacokinetics of nanoemulsions Curr. Drug Metab. 13 2012 396 417
18. R.M. Mader, G.G. Steger, K. Moser, H. Rainer, P. Krenmayr, and C. Dittrich Instability of the anticancer agent etoposide under in vitro culture conditions Cancer Chemother. Pharmacol. 27 1991 354 360
19. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63 (Pubitemid 14203433)
20. I.A. Najar, S.C. Sharma, G.D. Singh, S. Koul, P.N. Gupta, S. Javed, and R.K. Johri Involvement of P-glycoprotein and CYP 3A4 in the enhancement of etoposide bioavailability by a piperine analogue Chem. Biol. Interact. 190 2011 84 90
21. M.F. Paine, M. Khalighi, J.M. Fisher, D.D. Shen, K.L. Kunze, C.L. Marsh, J.D. Perkins, and K.E. Thummel Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J. Pharmacol. Exp. Ther. 283 1997 1552 1562 (Pubitemid 28016533)
22. M.F. Paine, D.D. Shen, K.L. Kunze, J.D. Perkins, C.L. Marsh, J.P. McVicar, D.M. Barr, B.S. Gillies, and K.E. Thummel First-pass metabolism of midazolam by the human intestine Clin. Pharmacol. Ther. 60 1996 14 24 (Pubitemid 26279216)
23. S. Pang, N. Zheng, C.A. Felix, J. Scavuzzo, R. Boston, and I.A. Blair Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry J. Mass Spectrom. 36 2001 771 781 (Pubitemid 32737419)
24. J.H. Park, and T.H. Kim Release of cytochrome c from isolated mitochondria by etoposide J. Biochem. Mol. Biol. 38 2005 619 623
25. D. Patel, and K.K. Sawant Self micro-emulsifying drug delivery system: formulation development and biopharmaceutical evaluation of lipophilic drugs Curr. Drug Deliv. 6 2009 419 424
26. B.D. Rege, J.P. Kao, and J.E. Polli Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers Eur. J. Pharm. Sci. 16 2002 237 246
27. X. Ren, X. Mao, L. Cao, K. Xue, L. Si, J. Qiu, A.D. Schimmer, and G. Li Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro Eur. J. Pharm. Sci. 36 2009 401 411
28. X. Ren, X. Mao, L. Si, L. Cao, H. Xiong, J. Qiu, A.D. Schimmer, and G. Li Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration Eur. J. Pharm. Biopharm. 70 2008 279 288
29. X. Sha, G. Yan, Y. Wu, J. Li, and X. Fang Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells Eur. J. Pharm. Sci. 24 2005 477 486 (Pubitemid 40387261)
30. J.C. Shah, J.R. Chen, and D. Chow Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide Pharm. Res. 6 1989 408 412 (Pubitemid 19176085)
31. G. Toffoli, G. Corona, B. Basso, and M. Boiocchi Pharmacokinetic optimisation of treatment with oral etoposide Clin. Pharmacokinet. 43 2004 441 466 (Pubitemid 38716503)
32. J.M. van Maanen, J. Retèl, J. de Vries, and H.M. Pinedo Mechanism of action of antitumor drug etoposide: a review J. Natl. Cancer Inst. 80 1988 1526 1533 (Pubitemid 19009648)
33. V.J. Wacher, J.A. Silverman, Y. Zhang, and L.Z. Benet Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics J. Pharm. Sci. 87 1998 1322 1330
34. B. Wahlang, Y.B. Pawar, and A.K. Bansal Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model Eur. J. Pharm. Biopharm. 77 2011 275 282
35. C.Y. Wu, L.Z. Benet, M.F. Hebert, S.K. Gupta, M. Rowland, D.Y. Gomez, and V.J. Wacher Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine Clin. Pharmacol. Ther. 58 1995 492 497
36. T. Yamagata, H. Kusuhara, M. Morishita, K. Takayama, H. Benameur, and Y. Sugiyama Effect of excipients on breast cancer resistance protein substrate uptake activity J. Control. Release. 124 2007 1 5 (Pubitemid 350088212)
37. S.H. Yang, H.G. Choi, S.J. Lim, M.G. Lee, and S.H. Kim Effects of morin on the pharmacokinetics of etoposide in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in female Sprague-Dawley rats Oncol. Rep. 29 2013 1215 1223
38. Y.M. Yin, F.D. Cui, C.F. Mu, M.K. Choi, J.S. Kim, S.J. Chung, C.K. Shim, and D.D. Kim Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation J. Control. Release. 140 2009 86 94
39. H. Zhang, M. Yao, R.A. Morrison, and S. Chong Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats Arch. Pharm. Res. 26 2003 768 772 (Pubitemid 43073795)
40. L. Zhang, G. Lin, Q. Chang, and Z. Zuo Role of intestinal first-pass metabolism of baicalein in its absorption process Pharm. Res. 22 2005 1050 1058 (Pubitemid 41127062)
41. T. Zhang, J. Chen, Y. Zhang, Q. Shen, and W. Pan Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide Eur. J. Pharm. Sci. 43 2011 174 179
42. X. Zhuo, N. Zheng, C.A. Felix, and I.A. Blair Kinetics and regulation of cytochrome P450-mediated etoposide metabolism Drug Metab. Dispos. 32 2004 993 1000 (Pubitemid 39096060)